Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

DSIP

Emideltide, DSIP nonapeptide, Delta sleep-inducing peptide

Quick Stats
Studies 458
Trials 82
Score 1
1990 pubmed 29 citations

Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration.

Minthon. L L; Edvinsson. L L; Ekman. R R; Gustafson. L L

Key Findings

  • s disease (DAT).",
  • ,

Practical Outcomes

  • The results are mainly descriptive and do not suggest any new treatment or supplement protocol. For biohackers, the study only hints that DSIP might serve as a biomarker for different dementias, but there is no actionable guidance on using DSIP for health optimization.

Summary

A study measured three brain chemicals in the spinal fluid of people with two kinds of dementia. It found that the peptide called DSIP was lower in Alzheimer's disease but a bit higher in frontotemporal dementia. Other chemicals (somatostatin and neuropeptide Y) also changed differently between the two diseases.

Abstract

The CSF levels of somatostatin-LI (SLI), neuropeptide Y (NPY-LI) and Delta Sleep Inducing Peptide (DSIP-LI) have been measured in patients with dementia of Alzheimer type (DAT) and dementia with frontotemporal degeneration of non-Alzheimer type (FTD). The distribution pattern of cortical degeneration differs between these two types of dementia. DAT shows degeneration of mainly temporo-parietal and temporo-limbic structures, whereas FTD discloses its main degeneration in the frontotemporal regions (Brun, 1987). The somatostatin-LI was significantly reduced both in DAT and FTD. NPY-LI showed a significant reduction in DAT but not in FTD. A tendency to a reduction with duration of the disease was observed in DAT whereas the contrary was noted in FTD. The DSIP-LI levels were reduced in DAT and slightly increased in FTD. The study provides an evidence of neurochemical differences between the two primary degenerative dementias.

Study Information

Provider

pubmed

Year

1990

DOI

10.1007/978-3-7091-3345-3_6

Citations

29

References

22